Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Esophageal StrictureEsophageal Neoplasms
Interventions
DRUG

Tranilast

Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.

DRUG

Dexamethasone

Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.

Trial Locations (3)

310009

Hangzhou Third People's Hospital, Hangzhou

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

312000

Shaoxing Central Hospital, Shaoxing

All Listed Sponsors
collaborator

The Third People's Hospital of Hangzhou

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER